Pharmacodynamic evaluation of BRII-693, a next-generation synthetic macrocyclic peptide antibiotic, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens.

Alexander J Lepak, Yali Zhu, David R Andes

Abstract read

In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexander J LepakDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Yali ZhuBrii Biosciences Department of Clinical Pharmacology, Brii Biosciences, Durham, North Carolina, USA.

David R AndesDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.ORCID 0000-0002-7927-9950

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRII-693 is a next-generation synthetic macrocyclic peptide antibiotic for infections caused by drug-resistant gram-negative pathogens. This study evaluated the pharmacodynamic activity of BRII-693 against common gram-negative pathogens using neutropenic mouse thigh (11 strains) and lung (15 strains) infection models. BRII-693 exhibited dose-dependent increases in pharmacokinetic exposure in both plasma and epithelial lining fluid (ELF). Due to its prolonged elimination half-life within ELF, the ELF area under the curve (AUC) was higher than plasma AUC on a mg/kg basis. In dose-ranging PK/PD studies, BRII-693 demonstrated dose-dependent antibacterial activity. In both the thigh and lung models, bacterial stasis was achieved at 24 h plasma AUC/MIC values of 1-19 for

Indexed as

Anti-Bacterial AgentsGram-Negative Bacterial InfectionsNeutropeniaPeptides, CyclicAcinetobacter baumanniiAnimalsArea Under CurveDisease Models, AnimalEscherichia coliFemaleGram-Negative BacteriaKlebsiella pneumoniaeLungMaleMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsPeptides, CyclicBRII-693gram-negativepharmacodynamics

Identifiers

PMID41746140

DOI10.1128/aac.01880-25

PMCPMC13041402

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.